A sensitive new method for clinically monitoring cytarabine concentrations at the DNA level in leukemic cells

Biochemical Pharmacology

Volumn 69, Issue 12, 2005, Pages 1795-1803

  Yamauchi, Takahiro ^a   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Acute leukemia; Cytarabine; Cytarabine triphosphate; DNA incorporation; Individualization; TDM

Indexed keywords

CYTARABINE; NUCLEOSIDE;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; ASSAY; CASE REPORT; CELL STRAIN HL 60; CONTROLLED STUDY; DNA DEGRADATION; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ISOLATION; DRUG MONITORING; EXPERIMENT; FEMALE; FRACTIONATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MALE; MEASUREMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOIMMUNOASSAY; SCINTILLATION; SENSITIVITY ANALYSIS; TECHNIQUE; TITRIMETRY;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CYTARABINE; DNA, NEOPLASM; DRUG MONITORING; FEMALE; HL-60 CELLS; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 20344377943     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.03.013     Document Type: Article

References (40)

1. A. Newland Progress in the treatment of acute myeloid leukemia in adults Int J Hematol 76 Suppl. 1 2002 253 258
2. E.F. Winton, and A.A. Langston Update in acute leukemia 2003: a risk adapted approach to acute myeloblastic leukaemia in adults Semin Oncol 31 2 Suppl. 4 2004 80 86
3. F. Ferrara Unanswered questions in acute myeloid leukaemia Lancet Oncol 5 2004 443 450
4. G.J. Ossenkoppele, P.W. Wijermans, J.J. Nauta, P.C. Huijgens, and M.M. Langenhuijsen Low-dose cytarabine for acute myeloid leukaemia and myelodysplastic syndromes: in vivo and in vitro cytotoxicity Eur J Cancer 27 1991 842 845
5. H.C. van Prooijen, A.W. Dekker, and K. Punt The use of intermediate-dose cytosine arabinoside (ID Ara-C) in the treatment of acute non-lymphocytic leukaemia in relapse Br J Haematol 57 1984 291 299
6. R.H. Herzig, S.N. Wolff, H.M. Lazarus, G.L. Phillips, C. Karanes, and G.P. Herzig High-dose cytosine arabinoside therapy for refractory leukemia Blood 62 1983 361 369
7. J.J. Furth, and S.S. Cohen Inhibition of mammalian DNA polymerase by the 5′-triphosphate of 1-β-d-arabinofuranosylcytosine and the 5′-triphosphate of 9-β-d-arabinofuranosyladenine Cancer Res 28 1968 2061 2067
8. A. Inagaki, T. Nakamura, and G. Wakisaka Studies on the mechanism of action of 1-β-d-arabinofuranosylcytosine as an inhibitor of DNA synthesis in human leukemic leukocytes Cancer Res 29 1969 2169 2176
9. D.W. Kufe, P.P. Major, E.M. Egan, and G.P. Beardsley Correlation of cytotoxicity with incorporation of ara-C into DNA J Biol Chem 255 1980 8997 9990
10. P.P. Major, E.M. Egan, G.P. Beardsley, M.D. Minden, and D.W. Kufe Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA Proc Natl Acad Sci USA 78 1981 3235 3239
11. F.L. Graham, and G.F. Whitmore The effect of 1-β-d- arabinofuranosylcytosine on growth, viability, and DNA synthesis of mouse L-cells Cancer Res 30 1970 2627 2635
12. F.L. Graham, and G.F. Whitmore Studies in mouse L-cells on the incorporation of 1-β-d-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 1-β-d-arabinofuranosylcytosine 5′-triphosphate Cancer Res 30 1970 2636 2644
13. D. Kufe, D. Spriggs, E.M. Egan, and D. Munroe Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells Blood 64 1984 54 58
14. P. Huang, and W. Plunkett Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event Cancer Chemother Pharmacol 36 1995 181 188
15. W. Plunkett, V. Hug, M.J. Keating, and S. Chubb Quantitation of 1-β-d-arabinofuranosylcytosine 5′-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-β-d- arabinofuranosylcytosine therapy Cancer Res 40 1980 588 591
16. J.O. Liliemark, W. Plunkett, and D.O. Dixon Relationship of 1-β-d-arabinofuranosylcytosine in plasma to 1-β-d- arabinofuranosylcytosine 5′-triphosphate levels in leukemic cells during treatment with high-dose 1-β-d-arabinofuranosylcytosine Cancer Res 45 1985 5952 5957
17. W. Plunkett, S. Iacoboni, E. Estey, L. Danhauser, J.O. Liliemark, and M.J. Keating Pharmacologically directed ara-C therapy for refractory leukemia Semin Oncol 12 Suppl. 3 1985 20 30
18. S.J. Iacoboni, W. Plunkett, and H.M. Kantarjian High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis J Clin Oncol 4 1986 1079 1088
19. W. Plunkett, J.O. Liliemark, and T.M. Adams Saturation of 1-β-d-arabinofuranosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-β-d-arabinofuranosylcytosine therapy Cancer Res 47 1987 3005 3011
20. V. Heinemann, E. Estey, M.J. Keating, and W. Plunkett Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia J Clin Oncol 7 1989 622 628
21. T. Yamauchi, T. Ueda, and T. Nakamura A new sensitive method for determination of intracellular 1-β-d-arabinofuranosylcytosine 5′-triphosphate content in human materials in vivo Cancer Res 56 1996 1800 1804
22. T. Yamauchi, S. Kishi, and Y. Kawai Pharmacokinetics of intracellular ara-CTP, an active metabolite of ara-C in leukemic cells from patients treated with ara-C including low-dose by a newly established assay Proc Am Soc Clin Oncol 17 1998 255a
23. T. Yamauchi, Y. Kawai, and S. Kishi Monitoring of intracellular 1-β-d-arabinofuranosylcytosine 5′-triphosphate in 1-β-d-arabinofuranosylcytosine therapy at low and conventional doses Jpn J Cancer Res 92 2001 546 553
24. D. Spriggs, G. Robbins, Y. Ohno, and D. Kufe Detection of 1-β-d-arabinofuranosylcytosine incorporation into DNA in vivo Cancer Res 47 1987 6532 6536
25. N. Shimada, T. Ueda, T. Yokoshima, J. Oh-ishi, and T. Oh-oka A sensitive and specific radioimmunoassay for 1-β-d-arabino-furanosylcytosine Cancer Lett 24 1984 173 178
26. G. Schmidt, and S.J. Thannhauser A method for the determination of desoxyribonucleic acid, ribonucleic acid, and phosphoproteins in animal tissues J Biol Chem 161 1945 83 89
27. W.C. Schneider Phosphorus compounds in animal tissues I. Extraction and estimation of desoxypentose nucleic acid and of pentose nucleic acid J Biol Chem 161 1945 293 303
28. W.C. Schneider Phosphorus compounds in animal tissues III. A comparison of methods for the estimation of nucleic acids J Biol Chem 164 1946 747 751
29. D.H.W. Ho, and E. Frei III Clinical pharmacology of 1-β-d- arabinofuranosylcytosine Clin Pharmacol Ther 12 1971 944 954
30. H.J. Fallon, E. Frei III, J.D. Davidson, J.S. Trier, and D. Burk Leukocyte preparations from human blood: evaluation of their morphologic and metabolic state J Lab Clin Med 59 1962 779 791
31. R.W. Davis, M. Thomas, J. Cameron, T.P. St John, S. Scherer, and R.A. Padgett Rapid DNA isolations for enzymatic and hybridization analysis Methods Enzymol 65 1980 404 411
32. A. Berneman, M. Lenfant, and M. Lambiotte Incorporation of tritiated thymidine into DNA of rat liver: a critique of various evaluation methods Biochimie 57 1975 773 777
33. L.-M. Wang, J.C. White, and R.L. Capizzi The effect of ara-C-induced inhibition of DNA synthesis on its cellular pharmacology Cancer Chemother Pharmacol 25 1990 418 424
34. K. Kamiya, M. Uchida, T. Ueda, and T. Nakamura Studies on intracellular kinetics of ara-C triphosphate in HL-60 human leukemia cells in relation to reasonable administration of ara-C J Jpn Soc Cancer Ther 25 1990 1419 1427
35. S. Ozawa, Y. Sugiyama, J. Mitsuhashi, and M. Inaba Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells Cancer Res 49 1989 3823 3828
36. C.M. Galmarini, X. Thomas, and F. Calvo In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia Br J Haematol 117 2002 860 868
37. P. Huang, S. Chubb, L.W. Hertel, G.B. Grindey, and W. Plunkett Action of 2′,2′-difluorodeoxycytidine on DNA synthesis Cancer Res 51 1991 6110 6117
38. L. Feng, G. Achanta, H. Pelicano, W. Zhang, W. Plunkett, and P. Huang Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage Int J Mol Med 5 2000 597 604
39. 4-behenoyl-1-β-d-arabinofuranosylcytosine in patients with acute leukemia Cancer Res 43 1983 3412 3416
40. T. Ueda, K. Kamiya, and Y. Urasaki Clinical pharmacology of 1-β-d-arabinofuranosylcytosine-5′-stearylphosphate, an orally administered long-acting derivative of low-dose 1-β-d- arabinofuranosylcytosine Cancer Res 54 1994 109 113